Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A medical researcher testing for antibodies against coronavirus. Photo: Karen Ducey/Getty Images

Some officials fear that the launch of antibody tests may become as problematic as the U.S.'s diagnostic testing effort, as fears rise about the tests' reliability and availability, the New York Times reports.

Why it matters: The tests show who has had the virus based on antibodies in their blood, even if they were asymptomatic. These people may have immunity from getting it again, although this is still unproven.

Between the lines: The antibody tests could be useful for gathering information about the true spread of the virus, and for potentially helping high-risk populations go back to work. But in both cases, that's only true if the tests are accurate and reliable.

  • The Food and Drug Administration has taken a loose regulatory approach to the tests, allowing most manufacturers coming on the market to validate their own tests. These tests, some experts warn, may not be high-quality.
  • Federal guidance regarding the tests is confusing, leading to some providers administering the tests who may not be authorized to do so, or misusing the tests to diagnose the coronavirus.
  • The tests also have a high false positive rate, and may run into the same manufacturing problems plaguing diagnostic tests.

The bottom line: Antibody tests are an important tool in our coronavirus response, but they're a long ways from where they need to be.

Go deeper: How coronavirus antibody tests will help

Go deeper

Jul 28, 2020 - Health

Pfizer beats Wall Street's expectations amid pandemic

Pfizer tallied a 29% profit margin in Q2. Photo: Erik McGregor/LightRocket via Getty Images

Drug sales at Pfizer dipped 11% in the second quarter, totaling $11.8 billion, but the pharmaceutical giant still reported more than $3.4 billion in net profits, or $0.78 in adjusted earnings per share — 15% above what Wall Street expected.

The big picture: The coronavirus pandemic only had a marginal effect on Pfizer, as the declining revenue was mostly due to lower sales from drugs that lost their patent protection. The focus is now on Pfizer's and BioNTech's coronavirus vaccine candidate, which started its late-stage clinical trial this week.

Jul 29, 2020 - Health

Reopening schools is a lose-lose dilemma for many families of color

Reproduced from KFF Health Tracking Poll; Note: Share includes responses for "very/somewhat worried", income is household income; Chart: Axios Visuals

Children of color have the most to lose if schools remain physically closed in the fall. Their families also have the most to lose if schools reopen.

Why it matters: The child care crisis created by the coronavirus pandemic is horrible for parents regardless of their race or income, but Black and Latino communities are bearing the heaviest burden.

Updated Oct 21, 2021 - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: Pfizer booster has 95.6% efficacy, large study shows — FDA authorizes mix-and-match for booster shots — J&J expects $2.5 billion of vaccine sales this year.
  2. Health: Cases and deaths keep falling — White House unveils plan to "quickly" vaccinate kids ages 5-11 — The global coronavirus vaccine gap — Gates Foundation to send $120 million of antiviral pills to lower-income countries.
  3. Politics: Reports: Brazil leader to be accused of crimes against humanity over COVID — Puerto Rico leads U.S. vaccination rates — Hawaii invites fully vaccinated travelers to return from Nov. 1.
  4. Education: Education secretary reveals limits to Biden’s mask push on states — LA extends deadline for school employee vaccinations — Parent sues Wisconsin school district after child tests positive.
  5. Variant tracker: Where different strains are spreading.